1. 1) Ministry of Health, Labour and Welfare. “The Japanese Pharmacopoeia Seventeen Edition,” 2016: 〈https://www.mhlw.go.jp/file/06-Seisakujouhou-11120000-Iyakushokuhinkyoku/JP17.pdf〉, cited 10 March, 2020.
2. 2) Ministry of Health, Labour and Welfare. “Supplement I to The Japanese Pharmacopoeia Seventeen Edition,” 2017: 〈https://www.mhlw.go.jp/file/06-Seisakujouhou-11120000-Iyakushokuhinkyoku/17-1.pdf〉, cited 10 March, 2020.
3. 3) Ministry of Health, Labour and Welfare. “Supplement II to The Japanese Pharmacopoeia Seventeen Edition,” 2019: 〈https://www.mhlw.go.jp/content/11120000/000522545.pdf〉, cited 10 March, 2020.
4. 4) Ministry of Health, Labour and Welfare. “The Japanese Pharmacopoeia Seventeen Edition, General Information, Quantitative Analytical Technique Utilizing Nuclear Magnetic Resonance (NMR),” 2016:〈https://www.mhlw.go.jp/file/06-Seisakujouhou-11120000-Iyakushokuhinkyoku/JP17_SANKOU.pdf〉, cited 10 March, 2020.
5. 5) Pharmaceuticals and Medical Devices Agency (PMDA). “JP drafts for public comments (3 June, 2019).”: 〈https://www.pmda.go.jp/rs-std-jp/standards-development/jp/pub-comments/jp/0161.html〉, cited 10 March, 2020.